|
|
|
| Effects of Camrelizumab Combined with TP Regimen on Efficacy Immune Function and Peripheral Blood VEGF bFGF CA125 and CEA in Patients with Intermediate to Advanced NSCLC |
| YU Dongshan, XIA Xiaoyang, CHEN Aimin, et al |
| Chuzhou Hospital Affiliated to Anhui Medical University / Chuzhou First People's Hospital, Anhui Chuzhou 239000, China |
|
|
|
|
Abstract Objective: To observe the effects of camrelizumab combined with TP chemotherapy regimen (paclitaxel + cisplatin) on efficacy, immune function, peripheral blood vascular endothelial growth factor (VEGF), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and basic fibroblast growth factor (bFGF) in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 102 patients with advanced NSCLC admitted to our hospital from January 2020 to January 2023 were selected and divided into two groups by simple random method. The control group was treated with TP regimen, and the observation group was additionally treated with camrelizumab. The effects, immune function, and peripheral blood factors of the two groups were compared, and the toxic and side effects of the two groups were counted. Results: The objective remission rate (ORR) and disease control rate (DCR) in the observation group were 56.86% (29/51) and 80.39% (41/51), which were higher than those in the control group (33.33% (17/51) and 58.82% (30/51), and the difference was statistically significant (P<0.05). Before treatment, there was no significant difference in VEGF, bFGF, CA125, CEA and immune function between the two groups (P>0.05). Compared with before treatment, VEGF, bFGF, CA125, CEA, and CD8+ decreased after treatment, while CD4+ and CD4+/CD8+ increased after treatment. The difference before and after treatment in the observation group was greater than that in the control group (P<0.05). There was no significant difference in the incidence of stomatitis, peripheral nerve abnormality, alopecia, bone marrow suppression, gastrointestinal reaction, abnormal liver or kidney function, reactive cutaneous capillary hyperplasia grade Ⅲ to grade Ⅳ between 2 groups (P>0.05). Conclusion: Camrelizumab combined with TP regimen in the treatment of advanced NSCLC can effectively improve ORR and DCR, improve immune function, inhibit the expression of VEGF, bFGF, CA125 and CEA in peripheral blood, while not increasing toxic and side effects.
|
|
|
|
|
|
[1] 朱宏财,岳丽娟,薛玲,等.多西他赛联合阿帕替尼二线治疗晚期非小细胞肺癌的疗效与安全性研究[J].海南医学,2022,33(24):3162-3166.
[2] 郝丽云,柳馨.卡瑞利珠单抗联合培美曲塞和顺铂对老年非小细胞肺癌患者的治疗效果[J].癌症进展,2022,20(19):1986-1989.
[3] 王丽.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2016,37(7):433-436.
[4] Mojsak D,Kuklinska B,Debczynski M,et al.Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2[J].Contemp Oncol (Pozn),2021,25(1):53-56.
[5] Le X,Nilsson M,Goldman J,et al.Dual EGFR-VEGF Pathway Inhibition:A Promising Strategy for Patients With EGFR-Mutant NSCLC[J].Thorac Oncol,2021,16(2):205-215.
[6] 陆友国,夏丽丽,朱洋,等.脾多肽联合TP方案对非小细胞肺癌患者TLR4、PD-1、HMGB1水平的影响[J].医学综述,2022,28(6):1234-1239.
[7] 王玲,杜倩宇,王西勇.安罗替尼联合化疗治疗驱动基因阴性晚期非小细胞肺癌的疗效及对血清VEGF、bFGF、MMP-9水平的影响[J].临床和实验医学杂志,2022,21(1):39-43.
[8] 钟萍,张军,凌华.非小细胞肺癌患者血清CA125、TIMP-1、SAA水平与临床病理特征和预后的关系[J].临床肺科杂志,2022,27(9):1411-1415.
[9] 孙铮,李勇.卡瑞利珠单抗联合化疗对比化疗在晚期鳞状非小细胞肺癌一线治疗中的成本效果分析[J].中国医院药学杂志,2022,42(20):2148-2152.
[10] 朱露莎,王松华,李进冬.卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的效果及安全性的真实世界研究[J].中国医药导报,2021,18(35):110-112,116.
[11] 卢伟,马西淼,李礼,等.卡瑞利珠单抗联合阿帕替尼治疗中晚期非小细胞肺癌的疗效[J].西北药学杂志,2023,38(1):188-192. |
|
|
|
2023, Vol. 29 
